A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus.

MLA

Thompson, Melanie, et al. “A 48-Week Randomized Phase 2b Study Evaluating Cenicriviroc versus Efavirenz in Treatment-Naive HIV-Infected Adults with C-C Chemokine Receptor Type 5-Tropic Virus.” AIDS (London, England), vol. 30, no. 6, Mar. 2016, pp. 869–78. EBSCOhost, https://doi.org/10.1097/QAD.0000000000000988.

APA

Thompson, M., Saag, M., DeJesus, E., Gathe, J., Lalezari, J., Landay, A. L., Cade, J., Enejosa, J., Lefebvre, E., & Feinberg, J. (2016). A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. AIDS (London, England), 30(6), 869–878. https://doi.org/10.1097/QAD.0000000000000988

Chicago

Thompson, Melanie, Michael Saag, Edwin DeJesus, Joseph Gathe, Jay Lalezari, Alan L Landay, Jerry Cade, Jeffrey Enejosa, Eric Lefebvre, and Judith Feinberg. 2016. “A 48-Week Randomized Phase 2b Study Evaluating Cenicriviroc versus Efavirenz in Treatment-Naive HIV-Infected Adults with C-C Chemokine Receptor Type 5-Tropic Virus.” AIDS (London, England) 30 (6): 869–78. doi:10.1097/QAD.0000000000000988.